Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

12 results about "Peptic ulcer" patented technology

A perforation or hole in the lining of the small intestine, lower esophagus or stomach.

Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.
Owner:EPITRACKER INC

Rabeprazole pharmaceutical composition as well as preparation method and application thereof

The invention discloses a rabeprazole pharmaceutical composition as well as a preparation method and application thereof. The invention provides a rabeprazole pharmaceutical composition, the rabeprazole pharmaceutical composition comprises an active pharmaceutical ingredient and an antacid, and the active pharmaceutical ingredient is selected from one or more of rabeprazole, rabeprazole sodium, other pharmaceutically acceptable salt forms, solvates and hydrates thereof. The rabeprazole pharmaceutical composition disclosed by the invention can inhibit the rabeprazole sodium from being damaged by gastric acid, and is small in side effect, rapid in treatment, relatively good in effect and high in patient compliance; the rabeprazole pharmaceutical composition has the advantages that the rabeprazole pharmaceutical composition is simple in preparation process and good in market prospect, and is an excellent medicine for treating peptic ulcer, and a pharmaceutical preparation can be delivered into the stomach by nasal feeding for some patients who cannot be administered by themselves, so that the effect of treating stomach diseases is achieved.
Owner:SHANGHAI BOCIMED PHARMA CO LTD +2

Pharmaceutical composition of rabeprazole, preparation method therefor and use thereof

PCT designated stageWO2025171802A1Organic active ingredientsDigestive systemPeptic ulcerPharmaceutical drug
A pharmaceutical composition of rabeprazole for treating peptic ulcers, a preparation method therefor and the use thereof. The composition contains a pharmaceutically active ingredient and an antacid, wherein the pharmaceutically active ingredient is selected from one or more of rabeprazole, rabeprazole sodium, and other pharmaceutically acceptable salt forms, solvates and hydrates of rabeprazole.
Owner:SHANGHAI BOCIMED PHARMA CO LTD +2

Composition of arctium lappa and lithospermum erythrorhizon, method for preparing same, and use thereof

PCT designated stageWO2025218712A1Digestive systemPlant ingredientsHelicobacterArctium lappa
Provided is a composition of Arctium lappa and Lithospermum erythrorhizon and a method for preparing same. The composition comprises an A. lappa extract and an L. erythrorhizon extract, wherein the A. lappa extract accounts for 90%-10% of the composition, in percentage by weight; the L. erythrorhizon extract accounts for 10%-90% of the composition, in percentage by weight. The composition can be used for preparing a pharmaceutical composition for preventing or treating peptic ulcer or for resisting Helicobacter pylori.
Owner:KANG BIOTECH

Natural pharmaceutical composition for treatment of peptic ulcer

The invention relates to a natural pharmaceutical composition for prevention and treatment of gastric ulcer and a preparation method of the natural pharmaceutical composition. The natural pharmaceutical composition comprises active natural medicinal ingredients. It is composed of turpentine oil, black seed oil, vitamin D and hyaluronic acid. The natural pharmaceutical composition provides a significant synergistic effect, combining anti-inflammatory, antibacterial, and gastroprotective properties, while also ensuring cost-effectiveness and minimal side effects compared to conventional treatments. Beside gastric ulcer is effective in relief of symptoms associated with gastric ulcer. The natural composition has the advantages of accurate curative effects, preparation stability, simplicity and feasibility in process and suitableness for industrial production.
Owner:GHADERI ADEL +2

Imidazo [1, 2-a] pyridine compound as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to an imidazo [1, 2-a] pyridine compound as well as a preparation method and application thereof. The structural formula of the imidazo [1, 2-a] pyridine compound is shown in the specification, and R is selected from sodium ions, potassium ions, calcium ions, magnesium ions, lithium ions or ammonium ions; when R is a sodium ion, a potassium ion, an ammonium ion or a lithium ion, n = 2; and when R is a calcium ion or a magnesium ion, n = 1. The imidazo [1, 2-a] pyridine compound provided by the invention shows high solubility, high dissolution rate and excellent biological activity for inhibiting gastric acid secretion, and provides a new choice for treating gastric acid related diseases such as peptic ulcer.
Owner:CHONGQING HUAPONT PHARMA +1

Polymorphs of asiaticoside, processes for their preparation and medical uses thereof

The present application discloses polymorphs of asiaticoside, a preparation method and medical use thereof. The present application firstly proves that asiaticoside has polymorphism, and provides various crystal forms of asiaticoside suitable for being used as a raw material, which can be used for developing asiaticoside preparations with controllable quality. The present application provides a simple, easy and environment-friendly preparation method of the polymorphs of asiaticoside, which is suitable for large-scale production. The polymorphs of asiaticoside or pharmaceutical compositions containing the crystal forms of asiaticoside can be used for preventing and treating diseases including type I interferon disease, peptic ulcer, Parkinson's disease, ulcerative colitis, systemic sclerosis, liver fibrosis, pulmonary fibrosis, renal fibrosis, Alzheimer's disease, depression, diabetic foot ulcer and refractory wound.
Owner:CHONGQING INNOVATION INSTITUTE CHINA PHARMACEUTICAL UNIVERSITY +1

Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes. Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Pharmaceutical composition for preventing or treating peptic ulcer

The invention relates to a pharmaceutical composition for preventing or treating peptic ulcer. The pharmaceutical composition comprises a compound shown in a formula I or pharmaceutically acceptable salt and a non-steroidal anti-inflammatory drug.
Owner:JIANGSU CAREFREE PHARM CO LTD

Crystal of benzimidazole compound as well as preparation method and application of crystal

The invention relates to the field of medicinal chemistry, relates to a crystal of a benzimidazole compound as well as a preparation method and application thereof, and in particular relates to a crystal of a compound as shown in a formula (I) and a preparation method thereof. The crystal of the compound shown in the formula (I) has good stability and can be applied to preparation of drugs for treating peptic ulcer.
Owner:SICHUAN KELUN PHARMA RES INST CO LTD

Imidazolo[1,2-a]pyridine compounds, their preparation methods and applications

This invention belongs to the field of biomedical technology, specifically relating to an imidazo[1,2-a]pyridine compound, its preparation method, and its applications. The imidazo[1,2-a]pyridine compound has the following structural formula: [Formula omitted for brevity]. Wherein, R is selected from sodium ions, potassium ions, calcium ions, magnesium ions, lithium ions, or ammonium ions; when R is a sodium ion, potassium ion, ammonium ion, or lithium ion, n=2; when R is a calcium ion or magnesium ion, n=1. The imidazo[1,2-a]pyridine compound provided by this invention exhibits high solubility, high dissolution rate, and excellent bioactivity in inhibiting gastric acid secretion, providing a new option for treating gastric acid-related diseases such as peptic ulcers.
Owner:CHONGQING HUAPONT PHARMA +1

Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipolar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.
Owner:EPITRACKER INC